Receptor, erbB-2
"Receptor, erbB-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell surface protein-tyrosine kinase receptor that is found to be overexpressed in a significant number of adenocarcinomas. It has extensive homology to and can heterodimerize with the EGF receptor (RECEPTOR, EPIDERMAL GROWTH FACTOR), the erbB-3 receptor (RECEPTOR, ERBB-3) and the erbB-4 receptor. Activation of the erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB receptor family members.
Descriptor ID |
D018719
|
MeSH Number(s) |
D08.811.913.696.620.682.725.400.150 D12.776.543.750.060.374 D12.776.543.750.750.400.350 D12.776.624.664.700.642 D23.101.840.642
|
Concept/Terms |
Receptor, erbB-2- Receptor, erbB-2
- Receptor, erbB 2
- erbB-2 Receptor
- erbB-2 Proto-Oncogene Protein
- Proto-Oncogene Protein, erbB-2
- erbB 2 Proto Oncogene Protein
- erbB-2 Receptor Protein-Tyrosine Kinase
- erbB 2 Receptor Protein Tyrosine Kinase
- HER-2 Proto-Oncogene Protein
- HER 2 Proto Oncogene Protein
- Proto-Oncogene Protein, HER-2
- neu Proto-Oncogene Protein
- Proto-Oncogene Protein, neu
- neu Proto Oncogene Protein
- Receptors, erbB-2
- Receptors, erbB 2
- erbB-2 Receptors
- Oncogene Protein HER-2
- Oncogene Protein HER 2
- p185(c-neu)
- Proto-Oncogene Protein HER-2
- Proto Oncogene Protein HER 2
- Proto-Oncogene Protein p185(neu)
- Proto-Oncogene Proteins c-erbB-2
- Proto Oncogene Proteins c erbB 2
- Receptor, neu
- c-erbB-2 Protein
- c erbB 2 Protein
- neu Receptor
|
Below are MeSH descriptors whose meaning is more general than "Receptor, erbB-2".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- Receptor, erbB-2 [D08.811.913.696.620.682.725.400.150]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.060]
- Receptor, erbB-2 [D12.776.543.750.060.374]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- Receptor, erbB-2 [D12.776.543.750.750.400.350]
- Neoplasm Proteins [D12.776.624]
- Oncogene Proteins [D12.776.624.664]
- Proto-Oncogene Proteins [D12.776.624.664.700]
- Receptor, erbB-2 [D12.776.624.664.700.642]
- Biological Factors [D23]
- Biological Markers [D23.101]
- Tumor Markers, Biological [D23.101.840]
- Receptor, erbB-2 [D23.101.840.642]
Below are MeSH descriptors whose meaning is more specific than "Receptor, erbB-2".
This graph shows the total number of publications written about "Receptor, erbB-2" by people in this website by year, and whether "Receptor, erbB-2" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1992 | 0 | 1 | 1 | 1993 | 0 | 1 | 1 | 1999 | 0 | 1 | 1 | 2002 | 0 | 4 | 4 | 2003 | 2 | 0 | 2 | 2004 | 1 | 0 | 1 | 2005 | 2 | 0 | 2 | 2006 | 2 | 1 | 3 | 2007 | 3 | 0 | 3 | 2008 | 2 | 2 | 4 | 2009 | 2 | 1 | 3 | 2010 | 5 | 3 | 8 | 2011 | 2 | 3 | 5 | 2012 | 3 | 4 | 7 | 2013 | 2 | 6 | 8 | 2014 | 1 | 6 | 7 | 2015 | 3 | 4 | 7 | 2016 | 6 | 7 | 13 | 2017 | 3 | 9 | 12 | 2018 | 3 | 9 | 12 | 2019 | 8 | 5 | 13 | 2020 | 4 | 3 | 7 | 2021 | 5 | 9 | 14 | 2022 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptor, erbB-2" by people in Profiles.
-
Polley MC. On the Quest of Risk Stratification in HER2-Positive Breast Cancer. J Natl Cancer Inst. 2022 03 08; 114(3):345-346.
-
Hassani D, Jeddi-Tehrani M, Yousefi P, Mansouri-Fard S, Mobini M, Ahmadi-Zare H, Golsaz-Shirazi F, Amiri MM, Shokri F. Differential tumor inhibitory effects induced by HER3 extracellular subdomain-specific mouse monoclonal antibodies. Cancer Chemother Pharmacol. 2022 03; 89(3):347-361.
-
Mascia F, Mazo I, Alterovitz WL, Karagiannis K, Wu WW, Shen RF, Beaver JA, Rao VA. In search of autophagy biomarkers in breast cancer: Receptor status and drug agnostic transcriptional changes during autophagy flux in cell lines. PLoS One. 2022; 17(1):e0262134.
-
Grushko TA, Filiaci VL, Montag AG, Apushkin M, Gomez MJ, Monovich L, Ramirez NC, Schwab C, Kesterson JP, Seward SM, Method MW, Olopade OI, Fleming GF, Birrer MJ. Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study. Appl Immunohistochem Mol Morphol. 2022 01 01; 30(1):27-35.
-
Catenacci DVT, Chung HC, Shen L, Moehler M, Yoon HH, Rosales MK, Kang YK. Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma. ESMO Open. 2022 02; 7(1):100360.
-
Le X, Cornelissen R, Garassino M, Clarke JM, Tchekmedyian N, Goldman JW, Leu SY, Bhat G, Lebel F, Heymach JV, Socinski MA. Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. J Clin Oncol. 2022 03 01; 40(7):710-718.
-
Clark AS, Yau C, Wolf DM, Petricoin EF, van 't Veer LJ, Yee D, Moulder SL, Wallace AM, Chien AJ, Isaacs C, Boughey JC, Albain KS, Kemmer K, Haley BB, Han HS, Forero-Torres A, Elias A, Lang JE, Ellis ED, Yung R, Tripathy D, Nanda R, Wulfkuhle JD, Brown-Swigart L, Gallagher RI, Helsten T, Roesch E, Ewing CA, Alvarado M, Crane EP, Buxton M, Clennell JL, Paoloni M, Asare SM, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Melisko M, Perlmutter J, Rugo HS, Schwab RB, Symmans WF, Hylton NM, Berry DA, Esserman LJ, DeMichele AM. Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial. Nat Commun. 2021 11 05; 12(1):6428.
-
Symmans WF, Yau C, Chen YY, Balassanian R, Klein ME, Pusztai L, Nanda R, Parker BA, Datnow B, Krings G, Wei S, Feldman MD, Duan X, Chen B, Sattar H, Khazai L, Zeck JC, Sams S, Mhawech-Fauceglia P, Rendi M, Sahoo S, Ocal IT, Fan F, LeBeau LG, Vinh T, Troxell ML, Chien AJ, Wallace AM, Forero-Torres A, Ellis E, Albain KS, Murthy RK, Boughey JC, Liu MC, Haley BB, Elias AD, Clark AS, Kemmer K, Isaacs C, Lang JE, Han HS, Edmiston K, Viscusi RK, Northfelt DW, Khan QJ, Leyland-Jones B, Venters SJ, Shad S, Matthews JB, Asare SM, Buxton M, Asare AL, Rugo HS, Schwab RB, Helsten T, Hylton NM, van 't Veer L, Perlmutter J, DeMichele AM, Yee D, Berry DA, Esserman LJ. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. JAMA Oncol. 2021 Nov 01; 7(11):1654-1663.
-
Moy B, Rumble RB, Come SE, Davidson NE, Di Leo A, Gralow JR, Hortobagyi GN, Yee D, Smith IE, Chavez-MacGregor M, Nanda R, McArthur HL, Spring L, Reeder-Hayes KE, Ruddy KJ, Unger PS, Vinayak S, Irvin WJ, Armaghani A, Danso MA, Dickson N, Turner SS, Perkins CL, Carey LA. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. J Clin Oncol. 2021 12 10; 39(35):3938-3958.
-
Polley MC, Dickler MN, Sinnwell J, Tenner K, de la Haba J, Loibl S, Goetz MP, Bergh J, Roberston J, Couch F, Ellis MJ, Martin M. A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy. Breast Cancer Res Treat. 2021 Aug; 189(1):15-23.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|